Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes

INTRODUCTION: In a preceding trial comparing two different titration schemes, insulin degludec/insulin aspart (IDegAsp) showed good efficacy for achieving HbA(1c) <7% when administered twice daily (BID) in patients with uncontrolled type 2 diabetes (T2D). However, poor glycemic control persisted...

Descripción completa

Detalles Bibliográficos
Autores principales: Bebakar, Wan Mohamaed Wan, Chaykin, Louis, Hersløv, Malene Lundgren, Rasmussen, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306112/
https://www.ncbi.nlm.nih.gov/pubmed/27853981
http://dx.doi.org/10.1007/s13300-016-0213-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306112/
https://www.ncbi.nlm.nih.gov/pubmed/27853981
http://dx.doi.org/10.1007/s13300-016-0213-8

Ejemplares similares